

White Paper

Hunger Killer Amlexanox 6C™ Homeopathic Oral Spray (Organic Alcohol Base)

Clinical Overview for Weight Loss Support & Appetite Management

Hunger Killer Amlexanox 6C™ is a homeopathic oral spray made in an organic alcohol base, designed to support:

- Reduced appetite and food intake
- Craving control
- Healthy weight management
- Metabolic support for weight-loss success

The product is based on the scientific understanding that metabolic inflammation influences hunger signaling and weight regulation, and that targeting inflammation pathways can support healthier metabolic function and improved weight outcomes.

The Weight-Loss Challenge: Why Appetite Control Matters

Many patients aiming to lose weight face common barriers such as:

- Persistent hunger despite calorie reduction
- Strong cravings that reduce adherence
- Difficulty sustaining progress long-term

Modern research increasingly supports that inflammation and metabolic imbalance can contribute to weight gain and insulin resistance, which is why metabolic-focused appetite tools are clinically valuable.

Why Amlexanox is Clinically Interesting for Weight Loss Support

Amlexanox is recognized as a compound with strong anti-inflammatory properties, and it has gained attention for its potential role in supporting metabolic balance.

A key highlight: after decades of use in other clinical areas, research has emphasized amlexanox as a compound that may help address obesity-related metabolic dysfunction by targeting inflammatory pathways.

Positive Mechanism Summary

1) Supports reduced food intake

Research summarized in the source describes amlexanox as acting through metabolic and inflammation-related pathways associated with reduced food intake and healthy weight management support.

2) Supports healthy metabolic efficiency

Mechanisms discussed include metabolic boosting and improved efficiency of white adipose tissue (WAT), supporting weight-management physiology.

3) Targets key enzymes linked to obesity-related inflammation

Two enzymes strongly associated with inflammatory and metabolic disease activity in obesity models include:

- IKK ϵ (I κ B kinase- ϵ)
- TBK1 (TANK-binding kinase-1)

Amlexanox is described as an IKK ϵ /TBK1 inhibitor, which aligns with weight-loss strategies that focus on improving metabolic regulation by reducing inflammation burden.

Positive Metabolic Benefits Supporting Weight Loss

In the referenced scientific summary, amlexanox is observed to:

- Increase energy expenditure
- Support factors related to enhanced insulin sensitivity
- Support improvement in fasting blood glucose levels

These metabolic improvements are important because successful weight loss is strongly supported by:

- Better energy utilization
- Healthier glucose metabolism
- Reduced metabolic resistance to fat loss

Weight-Loss Positioning for Doctors & Clinics

Hunger Killer Amlexanox 6C™ fits naturally into clinic programs that support:

- Appetite control + reduced caloric intake
- Sustainable lifestyle-based weight loss
- Metabolic wellness plans
- Patient adherence through convenient delivery

This product is especially relevant for:

- Medical weight-loss clinics
- Wellness and longevity clinics
- Functional medicine practices
- Integrative weight management programs

Product Format Advantages

Homeopathic oral spray delivery offers practical advantages in a weight-loss program:

- Easy to use
- Fast, convenient administration
- Supports compliance and consistency

Prepared in an organic alcohol base, making it suitable for clinics seeking clean-label, wellness-oriented delivery formats.

Summary for Clinical Teams

Hunger Killer Amlexanox 6C™ homeopathic oral spray is a compelling weight-loss support product because it aligns with modern research showing that:

- Inflammation contributes to obesity and insulin resistance
- Supporting metabolic inflammation balance can promote healthier weight outcomes
- Amlexanox is associated with reduced food intake, improved energy expenditure, and better metabolic function markers

References (Weight Loss & Metabolic Focus)

- Koch L. Teaching an old drug new tricks—amlexanox targets inflammation to improve metabolic dysfunction. *Nat Rev Endocrinol.* 2013.
- Reilly SM, Chiang SH, Decker SJ, et al. An inhibitor of TBK1 and IKK- β improves obesity-related metabolic dysfunctions in mice. *Nat Med.* 2013.
- Oral EA, Reilly SM, Gomez AV, et al. Inhibition of IKK β and TBK1 improves glucose control in a subset of patients with type 2 diabetes. *Cell Metab.* 2017.
- Reilly SM, Abu-Odeh M, Ameka M, et al. FGF21 is required for the metabolic benefits of IKK ϵ /TBK1 inhibition. *J Clin Invest.* 2021.